References
- Mauck KF and Clarke BL. Diagnosis, Screening, Prevention and Treatment of Osteoporosis. Mayo Clinic Proc 2006;81:662-72
- NHS: The Information Centre for health and social care. Hospital Episode Statistics for England. Inpatient statistics 2007-8. Available at:http://www.hesonline.org.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=214 [Last accessed 21 May 2010]
- Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2006;32:617-29
- Johansen A, Stone M. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 2000;11:551-2
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
- McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
- Dugard MN, Jones TJ, Davie MW. Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health 2010;64:518-22
- Shropshire. Wikipedia. 2009. Available at: http://en.wikipedia.org/wiki/Shropshire [Last accessed 21 May 2010]
- England ‘most crowded in Europe’. BBC news website. 2008. Available at: http://news.bbc.co.uk/1/hi/england/7618994.stm [Last accessed 21 May 2010]
- Department of Health. Our NHS our future: NHS next stage review. 2008. Available at: http://www.ournhs.nhs.uk/ [Last accessed 21 May 2010]
- NHS Sustainable Development Unit. NHS Carbon Reduction Strategy for England. 2009. Available at: http://www.sdu.nhs.uk/page.php?area_id = 2 [Last accessed 21 May 2010]
- What is a carbon footprint - definition. Time for a change. 2009. Available at: http://timeforchange.org/what-is-a-carbon-footprint-definition [Last accessed 21 May 2010]
- Running Costs for Petrol Cars. 2009, Available at: http://www.theaa.com/allaboutcars/advice/advice_rcosts_petrol_table.jsp. [Last accessed 17th May 2010]
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-20
- Lyles KW, Colon-Emeric C, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
- Department of Health. Payment by results: guidance and tariff for 2008-9. 2007. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081096 [Last accessed 21 May 2010]
- National Institute for Health and Clinical Excellence. Alendronate (review), etidronate (review), risedronate (review), raloxifene (review) strontium ranelate and teriparatide (review) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 161. 2008. Available at: http://www.nice.org.uk/Guidance/TA161 [Last accessed 21 May 2010]
- Kelly R, Taggart H. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 1997;315:1235
- British Orthopaedic Association. The care of patients with fragility fracture. 2007. Available at: http://www.fractures.com/pdf/BOA-BGS-Blue-Book.pdf [Last accessed 21 May 2010]
- World Health Organization. Adherence to long-term therapies: evidence for action. 2003. Available at: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf [Last accessed 21 May 2010]
- Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-19
- Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
- Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52
- Harrington JT. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 2005;53:198-204
- Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX® – assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-408
- NHS: The Information Centre for health and social care. Prescription Cost Analysis 2007. 2008 Available at: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-2007 [Last accessed 11 May 2009]
- Reid IR, Miller P, Lyles K. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908
- Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8